Evidence map›Paper›PMID 40791043›Full record

ArticleActas espanolas de psiquiatria2025

Insight in Individuals With First-episode Psychosis: Correlates With Symptoms, Neurocognition and Psychosocial Functioning Over Acute and Stable Phases.

Mar Mamano-Grande, Paola Punsoda-Puche, Victoria Espinosa, Judith Usall, Ana Barajas, Iris Baños, Bernardo Sánchez, Montse Dolz, Susana Ochoa

Abstract read
In one paragraph

Article in Actas espanolas de psiquiatria, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mar Mamano-GrandeParc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain.
Paola Punsoda-PucheParc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain.
Victoria EspinosaParc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain; Fundació Sant Joan de Déu, Esplugues de Llobregat, 08950 Barcelona, Spain; Institut de Recerca Sant Joan de Déu (IRSJD), Esplugues de Llobregat, 08950 Barcelona, Spain; Etiopatogènia i Tractament dels Trastorns Mentals Greus (MERITT), Institut de Recerca Sant Joan de Déu, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain.
Judith UsallParc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain; Fundació Sant Joan de Déu, Esplugues de Llobregat, 08950 Barcelona, Spain; Institut de Recerca Sant Joan de Déu (IRSJD), Esplugues de Llobregat, 08950 Barcelona, Spain; Etiopatogènia i Tractament dels Trastorns Mentals Greus (MERITT), Institut de Recerca Sant Joan de Déu, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Ana BarajasCentro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III, 28029 Madrid, Spain; Departament de Psicologia Clínica i de la Salut, Facultat de Psicologia, Universitat Autònoma de Barcelona, Bellaterra, Cerdanyola del Vallès, 08193 Barcelona, Spain; Serra Húnter Fellow, Generalitat de Catalunya, 08002 Barcelona, Spain; Centre d'Higiene Mental Les Corts, 08029 Barcelona, Spain.
Iris BañosParc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain.
Bernardo SánchezHospital Mutua de Terrassa, Terrassa, 08221 Barcelona, Spain.
Montse DolzHospital Sant Joan de Déu de Barcelona, Esplugues de Llobregat, 08906 Barcelona, Spain.
Susana OchoaParc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain; Institut de Recerca Sant Joan de Déu (IRSJD), Esplugues de Llobregat, 08950 Barcelona, Spain; Etiopatogènia i Tractament dels Trastorns Mentals Greus (MERITT), Institut de Recerca Sant Joan de Déu, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III, 28029 Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPoor insight is prevalent in individuals with first-episode psychosis (FEP) and is associated with unfavorable outcomes. Despite distinctions in insight characteristics between FEP and established schizophrenia, further research at this early stage is needed. This research investigates the relationship between insight and psychotic and depressive symptoms in acute and stable phases of FEP, as well as the association between insight, neuropsychological performance, and social functioning in the stable phase. Moreover, we explore how changes in insight correlate with symptom evolution between the two phases.

methodsNinety individuals with FEP were assessed at the acute and/or stable phases of the illness. Insight was assessed using the Scale to Assess Unawareness of Mental Disorder (SUMD) across three dimensions: insight into having a mental disorder (IMD), insight into the effects of medication (IEM), and insight into the social consequences (ISC) of having a mental disorder. Symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Schizophrenia Scale (CGI-SCH). A battery of cognitive tests was used to assess neurocognition, while social functioning was assessed with the Global Assessment of Functioning Scale (GAF) and the Disability Assessment Schedule (DAS-sv).

resultsDuring the acute phase, poor insight was significantly correlated with increased positive symptoms (IMD: p = 0.002; IEM: p = 0.003; ISC: p = 0.011) and general symptoms (IMD: p = 0.016; IEM p = 0.006). In the stable phase, insight remained significantly correlated with positive (IMD: p < 0.001; IEM: p = 0.010; ISC: p = 0.006) and general symptoms (IMD: p = 0.003; IEM: p = 0.023; ISC: p = 0.018). Negative symptoms (IMD: p = 0.002; IEM: p = 0.004; ISC: p = 0.004) and cognitive symptoms (via CGI-SCH) were also correlated with insight (IMD: p = 0.010; IEM: p = 0.020; ISC: p = 0.015). Neuropsychological performance was significantly associated to insight, with executive functioning correlating with IMD (Trail Making Test-A (TMT-A): p = 0.002; Trail Making Test-B (TMT-B): p = 0.014) and verbal memory correlating with IEM (short-term: p = 0.004; long-term: p = 0.043). Lower cognitive performance was associated with poorer insight (IMD: p = 0.002; IEM: p = 0.037; ISC: p = 0.008). Improved insight in IMD and ISC was associated with higher psychosocial functioning (GAF: p = 0.001; p = 0.005) and lower social disability (DAS-sv: p = 0.012; p = 0.004). Finally, insight improvements correlated with symptom reduction, as a decrease in PANSS positive symptoms was associated with better IMD (p < 0.001), while reduced general symptoms correlated with improved IEM (p = 0.024). IMD was the only dimension influenced by its acute-phase level (p = 0.004).

conclusionUnderstanding the implications of insight in the course and prognosis of psychosis is crucial for achieving positive outcomes. Targeting the three key insight dimensions (insight into illness, medication necessity and social consequences), with tailored interventions adapted to different illness stages can help optimize treatment response.

Indexed as

AwarenessCognitionPsychosocial FunctioningPsychotic DisordersAcute DiseaseAdolescentAdultFemaleHumansMaleNeuropsychological TestsYoung Adult

Identifiers

PMID40791043
PMCPMC12353227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.